Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1108663 | 0.87 | NMT1 (0.54) | ALDH1A1HSD17B10KMT2AKDM4EHPGD | |
| SCHEMBL14924463 | 0.85 | NMT1 (0.56) | ALDH1A1HSD17B10KDM4EHPGDNPSR1 | |
| SCHEMBL17450818 | 0.85 | NMT1 (0.56) | EGFRKDRTLR9 | |
| SCHEMBL13349310 | 0.84 | KDR (0.49) | CYP3A4CYP1A2CYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL14454200 | 0.83 | NPC1 (0.51) | CYP3A4CYP1A2CYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL2056410 | 0.83 | KDR (0.48) | CYP3A4CYP1A2CYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL1256123 | 0.83 | TSHR (0.60) | CYP3A4CYP1A2CYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL3383793 | 0.83 | ATR (0.51) | CYP3A4CYP1A2CYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL29036797 | 0.83 | FYN (0.60) | CYP3A4CYP1A2CYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL2961915 | 0.83 | BACE1 (0.51) | CYP3A4CYP1A2CYP2D6ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730878-B2 | Fused quinoline compounds as PI3K/mTOR inhibitors | Advenchen Pharmaceuticals, LLC (US) | 2020-08-04 | — | — | US | disclosed |
| EP-3319602-B1 | FUSED QUINOLINE COMPOUNDS AS PI3K/MTOR INHIBITORS | ADVENCHEN PHARMACEUTICALS LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3169687-B1 | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | ADVENCHEN PHARMACEUTICALS NANJING LTD (CN) | 2019-01-02 | — | — | EP | disclosed |
| US-20180201613-A1 | FUSED QUINOLINE COMPUNDS AS PI3K/mTOR INHIBITORS | Advenchen Pharmaceuticals, LLC (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180201613-A1 | FUSED QUINOLINE COMPUNDS AS PI3K/mTOR INHIBITORS | Advenchen Pharmaceuticals, LLC (US) | 2018-07-19 | — | — | US | disclosed |
| US-20170174687-A1 | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | ADVENCHEN PHARMACEUTICALS NANJING LTD (CN) | 2017-06-22 | — | — | US | disclosed |
| US-20170174687-A1 | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | ADVENCHEN PHARMACEUTICALS NANJING LTD (CN) | 2017-06-22 | — | — | US | disclosed |
| US-9624229-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| WO-2017011363-A1 | FUSED QUINOLINE COMPUNDS AS PI3K/MTOR INHIBITORS | Advenchen Pharmaceuticals, LLC (US) | 2017-01-19 | — | — | WO | disclosed |
| US-9433622-B2 | Pyrimidine compounds useful in the treatment of diseases mediated by IKKE and/or TBK1 mechanisms | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| US-8410155-B2 | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-02 | — | — | US | disclosed |
| US-8198456-B2 | e.g. 1,4-dihydro-4-(1H-indazol-5-yl)-2,6-dimethyl-3,5-pyridinedicarbonitrile; c-Met tyrosine kinase inhibitor; antitumor agent; lung, liver, gastric and breast solid tumors; pancreatic cancer, glioma, and hepatocellular carcinoma | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| EP-1981854-B1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20110039845-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-02-17 | — | — | US | disclosed |
| WO-2010030967-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH LLC (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
| US-20080176833-A1 | DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| WO-2008076805-A2 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2007070818-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070816-A2 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039845-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | H1-2, H1-3, H1-0 | CYP3A4 188/4885CYP1A2 66/4885CYP2D6 154/4885 |
| US-20170174687-A1 | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | MTOR, RICTOR, PIK3CA | CYP3A4 1874/4885CYP1A2 2609/4885CYP2D6 2577/4885 |
| US-10730878-B2 | Fused quinoline compounds as PI3K/mTOR inhibitors | MTOR, RICTOR, PIK3CA | CYP3A4 2061/4885CYP1A2 2767/4885CYP2D6 2770/4885 |
| US-20080176833-A1 | DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS | MET, DMPK, RET | CYP3A4 3417/4885CYP1A2 3348/4885CYP2D6 2019/4885 |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | MTOR, RICTOR, PIK3CA | CYP3A4 1355/4885CYP1A2 2131/4885CYP2D6 994/4885 |
| US-20180201613-A1 | FUSED QUINOLINE COMPUNDS AS PI3K/mTOR INHIBITORS | MTOR, RICTOR, PIK3CA | CYP3A4 1720/4885CYP1A2 2132/4885CYP2D6 2083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.